IMMUNOMODULATOR FOR TOPICAL TREATMENT OF MALIGNANT AND PREMALIGNANT LESIONS IN THE EPITHELIAL TISSUE LINING INSIDE AND OUTSIDE SURFACES OF THE BODY, the present invention provides a novel method of treatment for malignant and premalignant lesions in the epithelial tissue lining inside and outside surfaces, comprising the topical use of the immunomodulator, either alone or in association or combination with other drug and non-drug treatments and pharmaceutical compositions for its use.

The invention provides a method of sustained delivery of a tertiary amine-containing parent drug comprising administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile quaternary ammonium salts of tertiary amine-containing parent drugs (or tertiary imine-containing parent drugs) that are derivatized through aldehyde-linked prodrug moieties that reduce the solubility of the prodrug compound at a reference pH as compared to the parent drug. The physical, chemical and solubility properties of these derivatives can be further modulated by the choice of counterion X.sup.. In one embodiment, the present invention provides a prodrug compound of Formula I: ##STR00001##
where R.sub.1-R.sub.5 are defined in the written description of the invention. The prodrug compounds of the invention can be used to treat any condition for which the tertiary amine-containing parent drug or tertiary imine-containing parent drug is useful as a treatment.

A functional chemical consumption formulated for human consumption and useful for alleviating undesirable physiological effects. The chemical composition may be in liquid, food, or pill form and includes ingredients specifically to provide comfort for persons exposed to higher altitudes. Primary ingredients may include a combination of ammonium, chloride, and potassium ion.

A functional chemical consumption formulated for human consumption and useful for alleviating undesirable physiological effects. The chemical composition may be in liquid, food, or pill form and includes ingredients specifically to provide comfort for persons exposed to higher altitudes. Primary ingredients may include a combination of ammonium, chloride, and potassium ion.

A functional chemical consumption formulated for human consumption and useful for alleviating undesirable physiological effects. The chemical composition may be in liquid, food, or pill form and includes ingredients specifically to provide comfort for persons exposed to higher altitudes. Primary ingredients may include a combination of ammonium, chloride, and potassium ion.

The present invention is related to the use of a separate, sequential or simultaneous combination of at least one urinary acidifier with at least one calcium phosphate crystallization inhibitor for urine acidification, and thus preventing the pH at which supersaturation of calcium phosphate is produced and consequently, renal lithiasis.

The present invention is related to the use of a separate, sequential or simultaneous combination of at least one urinary acidifier with at least one calcium phosphate crystallization inhibitor for urine acidification, and thus preventing the pH at which supersaturation of calcium phosphate is produced and consequently, renal lithiasis.

A method of treating severe forms of PH, including PAH, in a patient is provided. The method includes administering at least one copper chelator comprising a tetrathiomolybdate (TTM) salt. The method may further include administering at least one active agent that enhances treatment such as methotrexate, inhibitors of the 5-lipoxygenase enzyme (5-LO), rituximab, baicalin, inhibitors of immune checkpoints CTLA-4, PD-1 and PDL-1, bufalin, quercetin, curcumin, integrins, inhibitors of NF-kappaB, and focal adhesion kinase inhibitors. Also provided is a composition including the TTM salt and the at least one active agent.

A method of treating severe forms of PH, including PAH, in a patient is provided. The method includes administering at least one copper chelator comprising a tetrathiomolybdate (TTM) salt. The method may further include administering at least one active agent that enhances treatment such as methotrexate, inhibitors of the 5-lipoxygenase enzyme (5-LO), rituximab, baicalin, inhibitors of immune checkpoints CTLA-4, PD-1 and PDL-1, bufalin, quercetin, curcumin, integrins, inhibitors of NF-kappaB, and focal adhesion kinase inhibitors. Also provided is a composition including the TTM salt and the at least one active agent.

A gel useful in reducing bacterial colonization in or around the area of a wound can be provided from at least one PEG and an aqueous composition having a pH of from 2 to 4, a total solute concentration of from 1.8 to 4.0 Osm/L, and from 0.9 to 1.7 g/L of at least one cationic surfactant. The aqueous composition can include a buffer system that includes an organic acid and a salt of an organic acid. The resulting gel is effective even when free of materials having antimicrobial properties other than those provided by the aqueous composition such as sporicides, antifungals and antibiotics.